Bloomberg Intelligence cover image

Lilly’s Zepbound Cuts Risk of Diabetes

Bloomberg Intelligence

00:00

Intro

This chapter explores Eli Lilly's stock growth, marking a notable 4% increase to a record high. It also highlights a study indicating that the company's weight loss medication significantly lowers diabetes risk, underscoring the potential of these 'wonder drugs' to transform health outcomes.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app